Antipsychotic Efficacies and Side Effects Evaluation and Head-To-Head Comparison of Xanomeline and KarXT in Preclinical Rodent Models of Schizophrenia (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR004.02 / N6; Pres time: Nov 14, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "Acute xanomeline dose dependently attenuated amphetamine induced hyperactivity in both mice and rats, and PCP induced hyperactivity and DOI induced head twitch response in mice...In rats, xanomeline dose dependently reduced CAR rate and increased escape latency in CAR test, and dose dependently reversed ketamine induced PPI deficit...Importantly, our head-to-head comparison demonstrates that KarXT selectively eliminates peripheral hypersalivation while fully preserving central antipsychotic efficacies. These findings provide critical, previously uncharacterized in vivo validation for this newly approved therapeutic combination."
Adverse events • Head-to-Head • Preclinical • CNS Disorders • Psychiatry • Schizophrenia
|